Treatment options for Parkinson's disease

Current Opinion in Neurology

Volumn 15, Issue 4, 2002, Pages 467-476

  Tintner, Ron ^a   Jankovic, Joseph ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Deep brain stimulation; Levodopa; Neuroprotection; Parkinson's disease; Surgery; Treatment

Indexed keywords

AMANTADINE; ANTIPARKINSON AGENT; APOMORPHINE; AROMATIC LEVO AMINO ACID DECARBOXYLASE INHIBITOR; BROMOCRIPTINE; CABERGOLINE; CATECHOL METHYLTRANSFERASE INHIBITOR; CHOLINERGIC RECEPTOR BLOCKING AGENT; DECARBOXYLASE INHIBITOR; DOMPERIDONE; DOPAMINE 1 RECEPTOR STIMULATING AGENT; DOPAMINE 2 RECEPTOR BLOCKING AGENT; DOPAMINE 2 RECEPTOR STIMULATING AGENT; DOPAMINE 3 RECEPTOR STIMULATING AGENT; DOPAMINE RECEPTOR STIMULATING AGENT; ENTACAPONE; GLUTAMATE RECEPTOR ANTAGONIST; LEVODOPA; LISURIDE; MODAFINIL; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NEUROPROTECTIVE AGENT; PERGOLIDE; PRAMIPEXOLE; REMACEMIDE; RILUZOLE; ROPINIROLE; SELEGILINE; TOLCAPONE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

BRAIN GRAFT; CELLULITIS; DEGENERATIVE DISEASE; DRUG INDUCED DISEASE; DYSKINESIA; EDEMA; EXPERIMENTAL SURGERY; HUMAN; LIVER INJURY; MESENCEPHALON; NEUROPROTECTION; PARKINSON DISEASE; POSTOPERATIVE COMPLICATION; PUBLICATION; REVIEW; SOMNOLENCE; SUBTHALAMIC NUCLEUS; TABLET; TISSUE TRANSPLANTATION;

ANTIPARKINSON AGENTS; ELECTRIC STIMULATION THERAPY; HUMANS; PARKINSON DISEASE;

EID: 0036315556     PISSN: 13507540     EISSN: None     Source Type: Journal    
DOI: 10.1097/00019052-200208000-00011     Document Type: Review

References (98)

1. Recent advances in the genetics and pathogenesis of Parkinson disease
2. Parkinson's disease is not one disease
3. Are dopamine receptor agonists neuroprotective in Parkinson's disease?
4. Current evidence for neuroprotective effects of nicotine and caffeine against Parkinson's disease
5. Neuroimmunophilin ligands exert neuroregeneration and neuroprotection in midbrain dopaminergic neurons
6. Systemic administration of the immunophilin ligand GPI 1046 in MPTP-treated monkeys
7. Impact of sustained deprenyl (selegiline) in levodopa-treated Parkinson's disease: A randomized placebo-controlled extension of the deprenyl and tocopherol antioxidative therapy of parkinsonism trial
8. Practice parameter: Initiation of treatment for Parkinson's disease. An evidence-based review. Report of the Quality Standards Subcommittee of the American Academy of Neurology
9. Levodopa strengths and weaknesses
10. Regulation of dopamine receptors and motor behavior following pulsatile and continuous dopaminergic replacement strategies in the MPTP primate model
11. Controlled release levodopa in Parkinson's disease: Influence of selection criteria and conversion recommendations in the clinical outcome of 450 patients
12. Duodenal levodopa infusion in Parkinson's disease: Long-term experience
13. Long-term comparative experience with tolcapone and entacapone in advanced Parkinson's disease
14. The catechol-O-methyltransferase (COMT) inhibitor entacapene enhances the pharmacokinetic and clinical response to Sinemet CR in Parkinson's disease
15. Efficacy and tolerability of entacapone as adjunctive therapy to levodopa in patients with Parkinson's disease and end-of-dose deterioration in daily medical practice: An open, multicenter study
16. The effects of different repeated doses of entacapone on the pharmacokinetics of L-Dopa and on the clinical response to L-Dopa in Parkinson's disease
17. Pharmacology of dopamine agonists in the treatment of Parkinson's disease
18. Long-term studies of dopamine agonists
19. Pramipexole versus levodopa as initial treatment for Parkinson disease: A four-year randomized controlled trial
20. Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression
21. The REAL-PET study: Slower progression in early Parkinson's disease treated with ropinirole compared to L-Dopa
22. Antiparkinsonian activity and dyskinesia risk of ropinirole and L-DOPA combination therapy in drug naive MPTP-lesioned common marmosets (Callithrix jacchus)
23. Switching from pergolide to pramipexole in patients with Parkinson's disease
24. Choosing dopamine agonists in Parkinson's disease
25. High-dose therapy with ropinirole in patients with Parkinson's disease
26. Efficacy of cabergoline in long-term use: Results of three observational studies in 1,500 patients with Parkinson's disease
27. Cabergoline versus bromocriptine for levodopa-induced complications in Parkinson's disease
28. Adrogolide HCI (ABT-431; DAS-431), a prodrug of the dopamine D1 receptor agonist, A-86929: Preclinical pharmacology and clinical data
29. Induction by dopamine D1 receptor agonist ABT-431 of dyskinesia similar to levodopa in patients with Parkinson disease
30. D1 dopamine receptors
31. Subcutaneous continuous apomorphine infusion in fluctuating patients with Parkinson's disease: Long-term results
32. A randomized, double-blind, placebo-controlled trial of subcutaneously injected apomorphine for parkinsonian off-state events
33. Efficacy and tolerability of a novel sublingual apomorphine preparation in patients with fluctuating Parkinson's disease
34. Intravenous apomorphine therapy in Parkinson's disease: Clinical and pharmacokinetic observations
35. Continuous transdermal dopaminergic stimulation in advanced Parkinson's disease
36. Transdermal dopaminergic D(2) receptor agonist therapy in Parkinson's disease with N-0923 TDS: A double-blind, placebo-controlled study
37. Efficacy and dose response of the novel transdermally applied dopamine agonist Rotigotine CDS in early Parkinson's disease
38. A comparison of dopamine agonists and catechol-O-methyltransferase inhibitors in Parkinson's disease
39. Ten-year follow-up of three different initial treatments in de-novo PD: A randomized trial
40. Sleep attacks and antiparkinsonian drugs: A pilot prospective pharmacoepidemiologic study
41. Interaction between dopamine and adenosine A2A receptors as a basis for the treatment of Parkinson's disease
42. Daytime sleepiness and other sleep disorders in Parkinson's disease
43. Modafinil and pramipexole-associated somnolence
44. Pergolide in the treatment of patients with early and advanced Parkinson's disease
45. Striatal molecular mechanisms and motor dysfunction in Parkinson's disease
46. A PET study with [11-C]raclopride in Parkinson's disease: Preliminary results on the effect of amantadine on the dopaminergic system
47. Amantadine for dyskinesia in patients affected by severe Parkinson's disease
48. Intravenous amantadine improves levadopa-induced dyskinesias: An acute double-blind placebo-controlled study
49. A randomized, double-blind, placebo-controlled, ascending-dose tolerability and safety study of remacemide as adjuvant therapy in Parkinson's disease with response fluctuations
50. A randomized, controlled trial of remacemide for motor fluctuations in Parkinson's disease
51. A double-blind, placebo-controlled and longitudinal study of riluzole in earry Parkinson's disease
52. Adenosine receptors and Parkinson's disease: Relevance of antagonistic adenosine and dopamine receptor interactions in the striatum
53. Caffeinated clues and the promise of adenosine A2A antagonists in PD
54. A double-blind crossover, placebo-controlled study of the adenosine A2A antagonist theophylline in Parkinson's disease
55. KW-6002 (Kyowa Hakko Kogyo)
56. Cannabinoids reduce levodopa-induced dyskinesia in Parkinson's disease: A pilot study
57. Neural mechanisms underlying peak-dose dyskinesia induced by levodopa and apomorphine are distinct: Evidence from the effects of the alpha(2) adrenoceptor antagonist idazoxan
58. Idazoxan, an alpha-2 antagonist, and L-DOPA-induced dyskinesias in patients with Parkinson's disease
59. Transdermal nicotine in PD: A randomized, double-blind, placebo-controlled study
60. A comparison of continuous thalamic stimulation and thalamotomy for suppression of severe tremor
61. Deep brain stimulation in the treatment of Parkinson's disease: A cost-effectiveness analysis
62. Quantitative and qualitative outcome measures after thalamic deep brain stimulation to treat disabling tremors
63. Deep-brain stimulation of the subthalamic nucleus or the pars interna of the globus pallidus in Parkinson's disease
64. Which target for DBS in Parkinson's disease? Subthalamic nucleus versus globus pallidus internus
65. Deep brain stimulation for the treatment of Parkinson's disease: Subthalamic nucleus versus globus pallidus internus
66. Deep brain stimulation of the subthalamic nucleus: Anatomical, neurophysiological, and outcome correlations with the effects of stimulation
67. The subthalamic nucleus in Parkinson's disease: Somatotopic organization and physiological characteristics
68. Deep brain stimulation of the subthalamic nucleus in Parkinson's disease: Effects of variation in stimulation parameters
69. Interactions between deep brain stimulation and levodopa in Parkinson's disease
70. Effect of bilateral stimulation of the subthalamic nucleus on parkinsonian voice
71. Chronic bilateral pallidal stimulation and levodopa do not improve gait in the same way in Parkinson's disease: A study using a video motion analysis system
72. Outcomes following staged bilateral pallidotomy in advanced Parkinson's disease
73. A 10-year follow-up review of patients who underwent Leksell's posteroventral pallidotomy for Parkinson disease
74. The subthalamic nucleus, hemiballismus and Parkinson's disease: Reappraisal of a neurosurgical dogma
75. Dorsal subthalamotomy for Parkinson's disease
76. Do unilateral ablative lesions of the subthalamic nucleus in parkinsonian patients lead to hemiballism?
77. Deep brain stimulator electrodes used for lesioning: Proof of principle
78. Enhancement of the response to levodopa therapy after intrastriatal transplantation of autologous sympathetic neurons in patients with Parkinson disease
79. Transplantation of embryonic dopamine neurons for severe Parkinson's disease
80. Blinded positron emission tomography study of dopamine cell implantation for Parkinson's disease
81. Parkinson's disease: Interpretations of transplantation study are erroneous
82. Immunophilin ligands can prevent progressive dopaminergic degeneration in animal models of Parkinson's disease
83. Embryonic stem cells develop into functional dopaminergic neurons after transplantation in a Parkinson rat model
84. Will embryonic stem cells be a useful source of dopamine neurons for transplant into patients with Parkinson's disease?
85. Dystonia and parkinsonism
86. In vivo evidence for differential association of striatal dopamine and midbrain serotonin systems with neuropsychiatric symptoms in Parkinson's disease
87. Comparison of pramipexole, fluoxetine, and placebo in patients with major depression
88. Management of psychosis in Parkinson's disease
89. Intrinsic and extrinsic psychosis in Parkinson's disease
90. Treatment options for depression and psychosis in Parkinson's disease
91. Clozapine for the treatment of drug-induced psychosis in Parkinson's disease: Results of the 12 week open label extension in the PSYCLOPS trial
92. Efficacy of olanzapine in the treatment of psychosis in dementia with Lewy bodies
93. Amoxapine shows an antipsychotic effect but worsens motor function in patients with Parkinson's disease and psychosis
94. Efficacy of rivastigmine in dementia with Lewy bodies: A randomised, double-blind, placebo-controlled international study
95. Rivastigmine in the treatment of parkinsonian psychosis and cognitive impairment: Preliminary findings from an open trial
96. An algorithm (decision tree) for the management of Parkinson's disease (2001): Treatment guidelines
97. Tremor and dopamine agonists
98. Subthalamic nucleus stimulation for Parkinson disease: Benefits observed in levodopa-intolerant patients